ARYx terminated all of its employees, including officers, after FDA delayed to 1Q11 a response to an SPA submitted for naronapride ( ATI-7505 ). ARYx said it was not able to obtain financing to continue...
Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date 12-mo op loss ended 12/31/09 1/7/10 Molecular Insight Pharmaceuticals Inc. (NASDAQ:MIPI) 13% to 61 $64.0 1.38 12/31/09 $46.3 Cuts are companywide; expects annual...
ARYx reduced headcount to fewer than 20 and hired Cowen and Co. to explore strategic options after partnering discussions for budiodarone fell through. The anti-arrhythmic amiodarone analog has completed a Phase IIb trial to treat...
Amgen Inc. (NASDAQ:AMGN) gained $0.90 to $57.38 last week after FDA approved a REMS for the use of erythropoiesis-stimulating agents (ESAs) in cancer patients. Amgen markets Aranesp darbepoetin alfa for cancer and renal indications and...
Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 9 mos ended 9/30 10/28/09 SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 17% to 34 $34.6 2.60 9/30/09 $10.0 Cuts primarily in R&D;...
ARYx restructured and reduced headcount by 17 (23%) to 56 with cuts companywide to focus on out-licensing its late stage compounds, including budiodarone . The anti-arrhythmic amiodarone analog has completed a Phase IIb trial to...
What might fit Company Product Description Indication Status Arca biopharma Inc. (NASDAQ:ABIO) Gencaro bucindolol Non-selective beta blocker Chronic heart failure FDA complete response letter in June requests additional clinical trials AtheroGenics Inc. (A) AGI-1067 Small...
On its way to becoming a bellwether biotech, Gilead Sciences Inc. saw its market cap jump some 50% in less than two years, climbing from about $26 billion in early 2006 to about $40 billion...
There some indications where it is hard to get new drugs approved, despite the obvious need, because patients on traditional treatments do so much better in the rigorous setting of a clinical trial than they...
Buysiders expect the summer months, as always, to be a little light on events. While some are hoping for a few dramatic upside moves among some neglected small caps, most buysiders were hesitant to disclose...